Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

The past decade has witnessed significant advances in the systemic treatment of advanced
hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies …

The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

The Wnt/β-catenin pathway comprises a family of proteins that play critical roles in
embryonic development and adult tissue homeostasis. The deregulation of Wnt/β-catenin …

Hepatocellular carcinoma (HCC) remains one of the most prevalent and deadliest cancers.
The poor outcome associated with HCC is dramatically changing due to the advent of …

Wnt/β-catenin signaling has been broadly implicated in human cancers and experimental
cancer models of animals. Aberrant activation of Wnt/β-catenin signaling is tightly linked with …

Hepatocellular carcinoma (HCC), the primary malignancy of hepatocytes, is a diagnosis with
bleak outcome. According to National Cancer Institute's SEER database, the average five …

The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death
worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol …

Mutation-induced activation of WNT–β-catenin signalling is a frequent driver event in human
cancer. Sustained WNT–β-catenin pathway activation endows cancer cells with sustained …